Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994051 | 0.79 | DYRK1A (0.46) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL13996528 | 0.79 | KEAP1 (0.50) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL23055232 | 0.79 | DYRK1A (0.46) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL3323525 | 0.77 | KMT2A (0.47) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL19599329 | 0.77 | PIK3CA (0.62) | DYRK1ACYP1A2TGFBR1TRIM33RET | |
| SCHEMBL4441720 | 0.76 | MEN1 (0.47) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL87222 | 0.75 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL16212292 | 0.74 | SUV39H2 (0.39) | DYRK1AKEAP1MAT2APIK3CGPRKDC | |
| SCHEMBL17790192 | 0.74 | KEAP1 (0.62) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL920398 | 0.74 | TSHR (0.48) | DYRK1AKEAP1TGFBR1TRIM33RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20240368168-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | ARTIVILA BIOPHARMA (CN) | 2024-11-07 | — | — | US | disclosed |
| CN-117751117-A | SARM1 enzyme activity inhibitor and application thereof | 科辉智药生物科技（无锡）有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| CN-115724839-A | SARM1 enzyme activity inhibitor and application thereof | 科辉智药生物科技(深圳)有限公司 | 2023-03-03 | — | — | CN | disclosed |
| WO-2023025244-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | 科辉智药生物科技(深圳)有限公司 | 2023-03-02 | — | — | WO | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| WO-2020252151-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | DYRK1A 4841/4885KEAP1 104/4885MEN1 4308/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | DYRK1A 3018/4885KEAP1 288/4885MEN1 2063/4885 |
| US-20240368168-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | SARM1, BACE1, SARNP | DYRK1A 4274/4885KEAP1 393/4885MEN1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.